For instance, TIL has been reported to attenuate hepatic inflammation in non-alcoholic fatty liver disease (NAFLD) by inhibiting NLRP3 inflammasome activation [55]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.